Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.49 |
| ▸ | ACACB | O00763 | 5/20 | 0.41 |
| ▸ | ACACA | Q13085 | 5/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12533192 | 0.85 | HRH3 (0.55) | HRH3 | |
| SCHEMBL13391005 | 0.81 | ACKR3 (0.47) | — | |
| SCHEMBL14077861 | 0.80 | ACKR3 (0.45) | — | |
| SCHEMBL14077794 | 0.80 | ACKR3 (0.47) | — | |
| SCHEMBL14078571 | 0.80 | ACKR3 (0.47) | — | |
| SCHEMBL14515330 | 0.77 | CYP3A4 (0.61) | CYP3A4CYP2D6 | |
| SCHEMBL13003545 | 0.77 | ACKR3 (0.41) | — | |
| SCHEMBL14456970 | 0.76 | CNR1 (0.48) | CYP3A4 | |
| SCHEMBL14355995 | 0.76 | ACKR3 (0.40) | — | |
| SCHEMBL13391321 | 0.76 | ACKR3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130385-A1 | Bicyclic Heterocylic Derivatives and Methods of Use | SCHERING CORPORATION | 2011-06-02 | — | — | US | disclosed |
| US-20110130385-A1 | Bicyclic Heterocylic Derivatives and Methods of Use | SCHERING CORPORATION | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130385-A1 | Bicyclic Heterocylic Derivatives and Methods of Use | GPR119, OXER1, INSR | HRH3 120/4885ACACB 105/4885ACACA 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.